Cue Biopharma is trading 5.5% down at $29.45 today as the stock pulls back following a sharp rally driven by a new licensing deal and financing-related momentum.
- The stock recently surged as investors reacted to the company's exclusive Ascendant-221 license and volatility linked to a reverse stock split.
- Today's decline appears to be a natural correction as traders digest recent gains rather than a reaction to fresh company-specific news.